Experimental gene therapies like AMT‑130 lower toxic huntingtin protein and significantly slow Huntington’s disease, offering ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 ...

Huntington's disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a progressive, hereditary brain disease that affects movement, cognition and emotions.

Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment ...

Teva's Honestly HD campaign, featuring Will Forte, aims to raise awareness about Huntington's disease through personal ...

Barbara Jacquelyn Sahakian receives funding from the Wellcome Trust. Her research work is conducted within the NIHR Cambridge Biomedical Research Centre (BRC) Mental Health and Neurodegeneration ...

The drugmaker has recruited Will Forte, who appeared on “SNL” for nearly a decade in the aughts, perhaps most memorably as ...

Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through ...

Medically reviewed by Huma Sheikh, MDKey TakeawaysThe medications approved by the Food and Drug Administration (FDA) for treating Huntington’s disease chorea are Xenazine (tetrabenazine), Ingrezza ...

Skyhawk Therapeutics announces interim results in patients from phase 1 clinical trial as a treatment for Huntington’s disease: Waltham, Massachusetts Thursday, January 29, 2026 ...

Symptoms caused by Huntington's disease include loss of motor control, involuntary movements, dementia, mood disorders, and psychiatric though disturbances.